IT Brief Asia - Technology news for CIOs & IT decision-makers
Story image
Robotic lung biopsy market may reach US$1,023 million by 2033: FMI
Thu, 18th May 2023

The robotic lung biopsy market size is projected to be worth US$408.0 million in 2023. From 2023 to 2033, global robotic lung biopsy demand is forecast to rise at 9.6% CAGR. As a result, total market valuation at the end of 2033 is expected to surpass US$1,023.05 million. These insights are based on a report, Robotic Lung Biopsy Market by Future Market Insights (FMI).

Lung cancer remains the primary cause of cancer deaths globally. To tackle this global burden, early diagnosis becomes highly critical. For this purpose, medical professionals perform diagnostic procedures such as biopsies and robotic lung biopsies.

“Robotic lung biopsy, also known as robotic-assisted bronchoscopy or robotic bronchoscopy, is a novel advancement in bronchoscopy. It is widely used to detect the presence of lung cancer and other lung diseases,” informs FMI. 

Robotic lung biopsies use robotic-assisted technology to perform precise biopsies quickly and accurately. These procedures are minimally invasive and can be instrumental in determining the stage and type of tumour, helping to guide the course of treatment.

The rising need for early detection and diagnosis of lung cancer provides a strong impetus to the robotic lung biopsy industry. Consequently, growing preferences towards minimally invasive medical procedures will boost robotic lung biopsy sales revenue during the forecast period.

Minimally invasive procedures such as robotic lung biopsies are safer and more effective and can reduce pain, recovery time, and risk of infection. In addition, they aid in the early detection of lung cancer and other lethal respiratory diseases, which can help initiate a proper treatment approach.

Surging lung cancer and other respiratory disease cases are likely to fuel robotic lung biopsy system demand during the assessment period.

“As per the World Cancer Research Fund International, there were an estimated 2.2 million lung cancer cases globally in 2020 and this number is expected to significantly increase during the next ten years. This will uplift robotic lung biopsy demand,” adds FMI in its report. 

The introduction of favourable reimbursement policies is expected to impact the robotic lung biopsy industry positively. Many insurance providers offer coverage for minimally invasive procedures, making them accessible and affordable to patients. As a result, more and more lung cancer patients are opting for robotic lung biopsies.

Due to the rising incidence of lung cancer and developments in robotic-assisted technology, the market for robotic lung biopsies is anticipated to expand rapidly over the next several years.

Collaborations between medical device manufacturers and research institutes are anticipated to increase. This will significantly expand the global robotic lung biopsy market size.

“Other drivers propelling the demand for robotic lung biopsy include the rising incidence of lung cancer globally will boost the global robotic lung biopsy industry. Lung cancer, according to the World Health Organization (WHO), is the primary reason for cancer-related deaths worldwide. High adoption of robotic systems for diagnosis of lung diseases will boost robotic lung biopsy system sales,” says FMI. 

Growing demand for minimally invasive procedures will likely create new opportunities for robotic lung biopsy system manufacturers.

The development of robotic-assisted technology is expected to fuel the market's expansion. Robotic technology helps doctors do minimally invasive operations that are extremely precise and accurate.

The market for robotic lung biopsies is expanding due to increased healthcare costs and government measures to increase access to healthcare.

According to the researchers at FMI, there are also some challenges for companies in the robotic lung biopsy market. 

“Healthcare organizations with tight budgets may be discouraged from adopting medical robotic technology because of the initial capital expense needed for buying and maintaining such equipment. The scarcity of qualified healthcare workers with experience in robotic-assisted lung biopsy operations is also limiting market expansion.”

There is a need for robust regulatory frameworks to monitor the creation and application of robotically assisted medical devices, given the field's quick speed of technological innovation. As numerous parties are involved in creating, distributing, and applying robotically assisted devices, guaranteeing product safety and regulatory compliance can be challenging.

Regarding the opportunities in the robotic lung biopsy industry, FMI argues, “The market for robotic lung biopsies offers the healthcare sector tremendous room for expansion and innovation. In addition, robotic lung biopsy devices are being used more often globally due to technological developments and rising demand for minimally invasive procedures."

“The market is anticipated to develop as a result of the expanding availability of sophisticated robotic technology as well as the rising number of hospitals and diagnostic centres around the world.”

“The robotic lung biopsy market presents a variety of chances for organizations to develop their operations, broaden their product lines, and alter their sources of income. The market is expected to expand in the next few years due to a growing emphasis on patient-centred and affordable healthcare.”

Developing new surgical robotics systems for robotic bronchoscopy will create lucrative opportunities for market players.

The use of cutting-edge technologies, such as artificial intelligence and machine learning, to increase the precision and effectiveness of biopsy procedures is one of the key trends in the market.

Creating more precise and compact biopsy tools and incorporating robotic systems with other imaging and diagnostic tools will boost the market. For instance, robots with CT or MRI imaging capabilities can deliver data that are even more exact and accurate than those obtained with conventional X-rays.

FMI's report also provides country-wise insights into the market. 

“High penetration of robotics in the healthcare sector and rising preference for minimally invasive procedures are key factors boosting the United States robotic lung biopsy market.”

“Other factors expected to drive the demand for robotic lung biopsies in the country are: Robotics and artificial intelligence developments have improved the procedure's accuracy, minimal invasiveness, and efficiency. This is resulting in increased patient satisfaction rates and lower healthcare expenses, which will fuel demand in the country.”

Older people are more likely to develop lung cancer and have problems with conventional biopsy techniques. As a result, robotic lung biopsy demand will surge robustly in the United States.

Robotic lung biopsy sales revenue in the United Kingdom is expected to surge at 8.2% CAGR during the assessment period. As a result, by 2033, the United Kingdom market value is projected to cross US$58.5 million.

The rising adoption of robotic technologies in disease diagnosis and treatment is a prominent factor driving the United Kingdom. Similarly, favourable government support will facilitate market expansion in the country.

The National Health Service (NHS) in the United Kingdom is also pushing for increased use of robotic technologies in healthcare. This is increasing both healthcare professionals' and patients' knowledge of these technologies and fuelling the adoption of cutting-edge medical equipment.

Robotic lung biopsy demand in China is anticipated to surge at 7.7% CAGR from 2023 to 2033. As a result, the total market valuation in China at the end of 2033 is expected to reach US$23.4 million. Increasing lung cancer cases are a key factor boosting China's robotic lung biopsy industry.

The development of this industry is also being aided by technological and robotic developments that have made lung biopsy procedures safer, less intrusive, and more effective.

Finally, the development of the robotic lung biopsy industry in China is significantly influenced by the Chinese government's support for medical technology and innovation.

Japan's robotic lung biopsy industry is estimated to reach a market share of US$37 million by 2033. It is expected to thrive at a CAGR of 9.7% over the next ten years. In addition, the growing adoption of advanced medical technologies is expected to boost Japan market during the assessment period.

Japan now has a sizeable market for precise diagnostic equipment, such as robotic lung biopsy systems. In the healthcare industry, Japan is renowned for being an early user of new technology, which has helped fuel this business's quick expansion.

“The Japanese government also places a high priority on encouraging medical innovation and funding the creation of cutting-edge technologies. This is creating a conducive environment for robotic lung biopsy device manufacturers,” concludes FMI.